
Regulus Therapeutics Unveils Q4-2024 Financial Results and Recent Updates: A New Chapter in Gene Therapy
Positive Interim Results in Phase 1b Clinical Trial of Farabursen (RGLS8429) for Autosomal Dominant Polycystic Kidney Disease Regulus Therapeutics, a biopharmaceutical company specializing in microRNA-targeted medicines, recently reported encouraging findings from the interim analysis of the fourth cohort in the Phase 1b multiple-ascending dose (MAD) clinical trial of their investigational drug, farabursen (RGLS8429), for the…